# Clover Health Investments share price today (Clover Health Investments, Corp., CLOV)

> Clover Health Investments, Corp.'s share price, valuation and earnings point in different directions. The next one or two quarters should make it clearer. CLOV · Healthcare · Healthcare Plans · data as of 3 November 2026. Page: https://www.sectoralpha.in/us/stocks/clov

Sector Alpha also publishes a daily newsletter that explains one Indian stock at a time: https://newsletter.sectoralpha.in/?utm_source=sectoralpha&utm_medium=ai_text&utm_campaign=llms

## Key numbers

- Price: $4.29 (+21.5% in a year)
- Revenue (Jun 2026): $743 M (+55.6% on a year ago)
- Profit (Jun 2026): $28.0 M
- Operating margin: 3.8% (+6.0 points on a year ago)
- ROE: −28%, FY25
- ROIC: −3.2%, against a 17.8% cost of capital: −21.0 points

Biggest thing to watch: the price has already been rising for 14 weeks, so timing is the risk more than the business. ## What is the Clover Health Investments share price today? Clover Health Investments, Corp.'s share price was $4.29 at the close on 3 November 2026. It has been rising for 14 weeks. That is 20.5% above its average price over the last 200 trading days. In the last 52 weeks it traded between $2 and $5, and at that close it sat 70% of the way up from that low. Over the past 13 weeks it has done worse than the S&P 500, and it has been behind for 1 week running. Over the last 6.4 years the share price moved −60% while the S&P 500 moved +144%, so it is behind the index over that whole period. It was last ahead over 13 weeks in the week of 30 October 2026. The chart above shows the 13-week comparison for every week. This page treats a rise as over when the price closes below its 200-day average on two Fridays in a row. ## What dividend does Clover Health Investments pay? Clover Health Investments, Corp. pays no dividend. In the last 12 reported quarters it declared no dividend per share, so there is no payout history to chart and no yield to show. Companies like this usually keep their earnings in the business, so the cash-flow sections show where that cash goes. ## Which stock lists is Clover Health Investments on? Clover Health Investments is not in the Nasdaq 100, the S&P 500 or the Dow Jones 30, and is not on the US tech stocks list. ## Is Clover Health Investments profitable? Clover Health Investments, Corp. earned $28.0 M of net profit in the Jun 2026 quarter. The full FY25 year was a loss of $85.5 M. That is 3.8% of the quarter's revenue. The same quarter a year earlier lost $10.6 M. 9 of the last 12 reported quarters were loss-making. ## How much revenue does Clover Health Investments make, and is it growing? Clover Health Investments, Corp. reported $743 M of revenue in the Jun 2026 quarter, +55.6% on the same quarter a year earlier. That is the 10th quarter in a row with growth on the year before. Over 4 years it has grown 9.0% a year on average. The last full year, FY25, came in at $1.9 B. The last four reported quarters add to $2.5 B. The quarterly figures for FY22 do not add up to the full-year total on file, so those quarters are left out of the charts and sums. FY25 revenue was $1.9 B, +40.3% on the year before. Recent pace: the last four quarters grew +53.0% on average, against 9.0% a year over the longer run, so this year is growing faster than its own long-run rate. Is growth speeding up? Revenue over the last 12 months grew +54.0%, against +37.1% a year over the last 8 quarters (accelerating). ## How much of every $100 of sales does Clover Health Investments keep? Clover Health Investments, Corp.'s operating margin was 3.8% in the Jun 2026 quarter, 6.0 percentage points higher than the same quarter a year ago. Across 5 years it has been between −46.8% and −3.4%. The latest quarter is above every full year in that period. Why: the operating margin move is clear, but the cost details behind it are not in our data, so we show the move without guessing the reason. ## Is Clover Health Investments' profit turning into cash? Clover Health Investments, Corp.'s cash-flow history is too short to judge how much of its profit turns into cash. In FY25 its operations used $66.9 M of cash, against −$85.5 M of profit. After null of spending on assets, free cash was −$69.0 M: it spent more than its operations brought in. Cash-flow figures here are yearly, because quarterly cash statements are not published, so this section changes once a year. What to look at next: no single use of cash stands out. The next section checks both the cash tied up in daily operations and the spending on assets. ## Where does Clover Health Investments' cash go? Clover Health Investments, Corp. does not report the customer, stock and supplier day counts a cash cycle needs, so this section looks at its spending on assets instead. Nothing is estimated in place of the missing day counts, so no cash-cycle chart is drawn. In short: neither the daily cycle nor new spending is soaking up the cash, so the picture is fairly clean. ## What is Clover Health Investments' P/E ratio, and how does it compare with its own history? Clover Health Investments, Corp. has no P/E right now, because its earnings are negative. The revenue and margin sections are where a turn would show first. Measured against sales instead, the market values Clover Health Investments, Corp. at 1.2× its FY25 revenue of $1.9 B. The P/E comes back here once profit turns positive. ## Is the Clover Health Investments business getting better or worse? Clover Health Investments, Corp.'s business trend cannot be read yet. There are fewer than eight usable quarters of growth figures, so there is not enough history to read the trend. This is based on 10 quarters of 2 measures, with some gaps. Why it matters: with too little history, we say so rather than guess a direction. One or more growth lines have an extreme jump caused by comparing with a near-zero or loss-making quarter. Those jumps are capped before reading and drawn at the edge of the chart, so one odd quarter does not decide the result. There are fewer than eight usable quarters, so this page does not guess a direction from so little history. ## How much does Clover Health Investments earn on its capital? Clover Health Investments, Corp. earned a ROE of −28% in FY25. That is up from a low of −109% in FY21. Its return on capital used (ROIC) is 21.0 percentage points below its cost of capital, so growth here does not yet pay for the capital it uses. It comes from a −4.4% net margin and 3.56× asset turnover (sales divided by assets). Why the return is what it is (FY25): a −4.4% net margin × 3.56× asset turnover × 1.75× leverage (assets divided by equity) ≈ −27.4% on equity. The margin does its share; borrowing is a big part of it. The key test, return on capital used minus the cost of capital: −3.2% − 17.8% = −21.0 percentage points. The 17.8% is an estimate of this company's own cost of capital. Read the sign and size of the gap, not the decimals. Negative: growth at these returns loses value until returns improve. ## Does Clover Health Investments have too much debt? Clover Health Investments, Corp. has total debt of $3.3 M against shareholder equity of $309 M as of Dec 2025, so its debt is 0.01× its equity, which is very little. Year by year, that ratio went from 0.05 in FY21 to 0.01 in FY25. So the returns on this page come from the business, not from borrowed money. ## What is the Clover Health Investments shareholding pattern? 6.3% of Clover Health Investments, Corp.'s tradable shares are in short positions, which are bets that the price will fall, so some traders are betting against it. At normal trading volumes, closing those positions would take about 5.7 days. US companies do not publish a quarter-by-quarter list of owners, so this page uses short interest instead. It is a single reading at one point in time; we do not have its history. Why it is at this level: the figure does not say who holds the short positions or why, so we show the level without guessing the story. ## How far is Clover Health Investments from balance-sheet trouble? For Clover Health Investments, Corp., the Z-score is not available, so we say so rather than guess one. It estimates how far the balance sheet is from trouble; it is not a forecast of failure. The debt, cash-flow and return sections show the balance-sheet figures we do have, each with its own date. ## How does Clover Health Investments rank in its industry? 55.1 out of 100, rank 9 of 11 in Healthcare Plans, with 45% of the evidence available. It is provisional, so it is ranked below companies with full evidence. Clover Health Investments, Corp. scores 55.1 out of 100 against the 11 companies it is compared with in Healthcare Plans, ranking 9. Some evidence is missing, so the score is pulled toward the middle on purpose. The four parts add up to the total exactly: 21.7 + 9.6 + 11.2 + 12.6 = 55.1. This is the same number shown on the industry page; it is worked out once for the whole group and read here. What would change it: The score would fall if profit growth turns negative or margins stop improving while the share price lags its sector. ## Which companies is Clover Health Investments compared with? Clover Health Investments ranks 9 of 11 Healthcare Plans companies on the 4-Factor Sector Score, with 55.1 out of 100. 1. [Progyny, Inc.](https://www.sectoralpha.in/us/stocks/pgny) PGNY · turning · Most evidence points up · 81% evidence 74.9 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 27.1/35 · Revenue 5.6% · Profit 47.2% · Operating margin change 4.1 points · 83% evidence Capital efficiency 21.1/25 · ROCE 25.2% · Operating margin 11.4% · 76% evidence Valuation 13.3/20 · P/E 28.7× · PEG 0.51 · 65% evidence Relative strength 13.4/20 · Lead over its industry 1.9% · Lead over S&P 500 12.5% · 1 year 29.9% · 100% evidence · 1 of 12 weeks ahead Exact sum: 27.1 + 21.1 + 13.3 + 13.4 = 74.9 · What this means: Earnings, capital efficiency and relative strength all agree. The open questions are about management, upcoming events and risks. 2. [The Cigna Group](https://www.sectoralpha.in/us/stocks/ci) CI · turning · Evidence leans up · 81% evidence 57.2 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 20.4/35 · Revenue 7.8% · Profit 27.9% · Operating margin change 0.3 points · 83% evidence Capital efficiency 13.8/25 · ROCE 11.8% · Operating margin 4% · 76% evidence Valuation 15.6/20 · P/E 11.4× · PEG 0.35 · 65% evidence Relative strength 7.4/20 · Lead over its industry -10.8% · Lead over S&P 500 0.2% · 1 year 11.7% · 100% evidence · 2 of 12 weeks ahead Exact sum: 20.4 + 13.8 + 15.6 + 7.4 = 57.2 · What this means: The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer. 3. [UnitedHealth Group Incorporated](https://www.sectoralpha.in/us/stocks/unh) UNH · turning · Evidence leans up · 65% evidence 51.4 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 14.6/35 · Revenue 3.4% · Profit -9.7% · Operating margin change 2 points · 71% evidence Capital efficiency 13.8/25 · ROCE n/a · Operating margin 5.8% · 30% evidence Valuation 13.1/20 · P/E 20.7× · PEG 0.72 · 65% evidence Relative strength 9.9/20 · Lead over its industry -2.3% · Lead over S&P 500 8.1% · 1 year 24.7% · 100% evidence · 0 of 12 weeks ahead Exact sum: 14.6 + 13.8 + 13.1 + 9.9 = 51.4 · What this means: The valuation scores well, but earnings are not improving yet, so the business does not back up the low multiple so far. 4. [Humana Inc.](https://www.sectoralpha.in/us/stocks/hum) HUM · breaking out · Evidence leans down · 62% evidence 49.1 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 14.1/35 · Revenue 18.3% · Profit -18.9% · Operating margin change -0.1 points · 62% evidence Capital efficiency 10.7/25 · ROCE n/a · Operating margin 3.5% · 30% evidence Valuation 6.4/20 · P/E 37.3× · PEG 2.13 · 65% evidence Relative strength 17.9/20 · Lead over its industry 22.9% · Lead over S&P 500 33.4% · 1 year 65.8% · 100% evidence · 9 of 12 weeks ahead Exact sum: 14.1 + 10.7 + 6.4 + 17.9 = 49.1 · What this means: Relative strength against the index is 33.4%, and revenue and profit growth are weak. 5. [Elevance Health, Inc.](https://www.sectoralpha.in/us/stocks/elv) ELV · turning · Evidence leans down · 77% evidence 40.9 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 14.5/35 · Revenue 3.6% · Profit -7.1% · Operating margin change 0.7 points · 71% evidence Capital efficiency 8.4/25 · ROCE 3.2% · Operating margin 4.2% · 76% evidence Valuation 8.6/20 · P/E 16.4× · PEG 2.05 · 65% evidence Relative strength 9.4/20 · Lead over its industry -3.5% · Lead over S&P 500 7.3% · 1 year 30.2% · 100% evidence · 4 of 12 weeks ahead Exact sum: 14.5 + 8.4 + 8.6 + 9.4 = 40.9 · What this means: The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer. 6. [Molina Healthcare, Inc.](https://www.sectoralpha.in/us/stocks/moh) MOH · turning · Evidence leans down · 67% evidence 40.7 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 8.3/35 · Revenue -1.8% · Profit -105.4% · Operating margin change -0.2 points · 71% evidence Capital efficiency 7.9/25 · ROCE 4.8% · Operating margin 1% · 76% evidence Valuation 11.5/20 · P/E -205.2× · PEG n/a · 15% evidence Relative strength 13.0/20 · Lead over its industry -0.3% · Lead over S&P 500 10.2% · 1 year 36.7% · 100% evidence · 3 of 12 weeks ahead Exact sum: 8.3 + 7.9 + 11.5 + 13 = 40.7 · What this means: Relative strength against the index is 10.2%, and revenue and profit growth are weak. 7. [CVS Health Corporation](https://www.sectoralpha.in/us/stocks/cvs) CVS · quiet · Evidence leans down · 81% evidence 38.4 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 18.8/35 · Revenue 7.4% · Profit 8.8% · Operating margin change 1.1 points · 83% evidence Capital efficiency 10.2/25 · ROCE 7.3% · Operating margin 3.9% · 76% evidence Valuation 4.4/20 · P/E 27× · PEG 4.83 · 65% evidence Relative strength 5.0/20 · Lead over its industry -9.6% · Lead over S&P 500 0.3% · 1 year 15.7% · 100% evidence · 0 of 12 weeks ahead Exact sum: 18.8 + 10.2 + 4.4 + 5 = 38.4 · What this means: The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer. 8. [Oscar Health, Inc.](https://www.sectoralpha.in/us/stocks/oscr) OSCR · turning · Too little evidence to rank firmly · 45% evidence 64.0 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 22.0/35 · Revenue 42.8% · Profit n/a · Operating margin change 16 points · 40% evidence Capital efficiency 11.7/25 · ROCE n/a · Operating margin 8% · 30% evidence Valuation 10.3/20 · P/E 15.6× · PEG n/a · 15% evidence Relative strength 20.0/20 · Lead over its industry 30.5% · Lead over S&P 500 40.8% · 1 year 82.9% · 100% evidence · 9 of 12 weeks ahead Exact sum: 22 + 11.7 + 10.3 + 20 = 64 · What this means: Some evidence is missing, so the score is pulled toward the middle on purpose. 9. Clover Health Investments, Corp. this page CLOV · quiet · Too little evidence to rank firmly · 45% evidence 55.1 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 21.7/35 · Revenue 54% · Profit n/a · Operating margin change 6 points · 40% evidence Capital efficiency 9.6/25 · ROCE n/a · Operating margin 3.8% · 30% evidence Valuation 11.2/20 · P/E -150.3× · PEG n/a · 15% evidence Relative strength 12.6/20 · Lead over its industry 14.1% · Lead over S&P 500 23.1% · 1 year 60.7% · 100% evidence · 3 of 12 weeks ahead Exact sum: 21.7 + 9.6 + 11.2 + 12.6 = 55.1 · What this means: Some evidence is missing, so the score is pulled toward the middle on purpose. 10. [Centene Corporation](https://www.sectoralpha.in/us/stocks/cnc) CNC · turning · Too little evidence to rank firmly · 45% evidence 53.8 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 19.7/35 · Revenue 12.9% · Profit -349.7% · Operating margin change 3.9 points · 40% evidence Capital efficiency 11.1/25 · ROCE n/a · Operating margin 3.8% · 30% evidence Valuation 10.9/20 · P/E -6.2× · PEG n/a · 15% evidence Relative strength 12.1/20 · Lead over its industry 12.3% · Lead over S&P 500 22.8% · 1 year 79.7% · 100% evidence · 5 of 12 weeks ahead Exact sum: 19.7 + 11.1 + 10.9 + 12.1 = 53.8 · What this means: Some evidence is missing, so the score is pulled toward the middle on purpose. 11. [Alignment Healthcare, Inc.](https://www.sectoralpha.in/us/stocks/alhc) ALHC · basing · Too little evidence to rank firmly · 45% evidence 36.1 out of 100 Growth Capital Valuation Relative

Missing figures are not scored as bad. They lower the confidence and pull the final score toward the middle. Relative strength counts only when the company has a reading for this week; with no reading, that factor is left out and its 20 points are shared across the other three in proportion. PEG is not shown when the ratio cannot mean anything: the company must be making a profit, its price-to-earnings must be positive, and its three-year earnings growth must fall between 5% and 60%. Dividing a price multiple by a loss, or by growth measured off a tiny base, produces a number that looks precise and tells you nothing. Under relative strength, one mark per week shows the last 12 weeks: a mark is filled where the company led S&P 500 by 5% or more over the 13 weeks ending that week, which is the same test used everywhere on this site. Price stage places the company on the same six-step path the industry is placed on (basing, turning, breaking out, leader, fading, asleep), read from how many weeks running it has led S&P 500 and whether that lead is growing or shrinking. It describes where the share price stands, not the direction of earnings, and it is not a recommendation; it is left blank for a company whose weekly history is too short or too stale to read. The figures in this ranking come from the industry comparison: results through the Sep 2026 quarter, and the P/E at that quarter's end. The sections above use the latest weekly price, so a P/E or return there can differ a little from the one here. The stage words in this ranking (such as losing its lead or breaking out) describe the lead over the index, not the price phase in the price section. Related companies: [Healthcare Plans](https://www.sectoralpha.in/us/sectors/healthcare-plans), all 11 compared on one page. ## Which companies are close to Clover Health Investments in size? Clover Health Investments is the 9th largest of 11 Healthcare Plans companies on Sector Alpha by market value (scores of 3 November 2026). Just above it: Humana Inc., Centene Corporation, Molina Healthcare, Inc. and Oscar Health, Inc. Just below it: Progyny, Inc. and Alignment Healthcare, Inc. ### Healthcare Plans companies close in size

1. [Humana Inc.](https://www.sectoralpha.in/us/stocks/hum) $50.2 billion
2. [Centene Corporation](https://www.sectoralpha.in/us/stocks/cnc) $33.4 billion
3. [Molina Healthcare, Inc.](https://www.sectoralpha.in/us/stocks/moh) $10.8 billion
4. [Oscar Health, Inc.](https://www.sectoralpha.in/us/stocks/oscr) $10 billion
5. Clover Health Investments, Corp. $2.3 billion
6. [Progyny, Inc.](https://www.sectoralpha.in/us/stocks/pgny) $2.2 billion
7. [Alignment Healthcare, Inc.](https://www.sectoralpha.in/us/stocks/alhc) $1.5 billion

[All 11 Healthcare Plans companies, largest first](https://www.sectoralpha.in/us/sectors/healthcare-plans#all-companies)

### Companies close in size in other industries

1. [Cohu, Inc.](https://www.sectoralpha.in/us/stocks/cohu) $2.3 billion · Semiconductor Equipment & Materials
2. [Recursion Pharmaceuticals, Inc.](https://www.sectoralpha.in/us/stocks/rxrx) $2.3 billion · Biotechnology
3. Clover Health Investments, Corp. $2.3 billion
4. [Rogers Corporation](https://www.sectoralpha.in/us/stocks/rog) $2.3 billion · Electronic Components
5. [Celldex Therapeutics, Inc.](https://www.sectoralpha.in/us/stocks/cldx) $2.3 billion · Biotechnology

## What else do people ask about Clover Health Investments? ### What were Clover Health Investments's latest quarterly results? Clover Health Investments, Corp. reported revenue of $743 M and net profit of $28.0 M for the Jun 2026 quarter. Earnings per share were $0.05. The operating margin was 3.8%, 6.0 percentage points higher than a year earlier (as of 3 November 2026). ### What is Clover Health Investments's market cap? Clover Health Investments, Corp.'s market capitalisation is $2.3 B at a stock price of $4.29. Market cap is the share price times the number of shares, so it changes whenever the price moves (as of 3 November 2026). ### How is Clover Health Investments performing? Clover Health Investments, Corp.'s share price has been rising for 14 weeks. Over the past 13 weeks it has done worse than the S&P 500, for 1 week running. This describes what the data did, not a rating (as of 3 November 2026). ### Will Clover Health Investments's stock price go up? This page does not forecast Clover Health Investments, Corp.'s stock price. What it shows instead: the stock price is $4.29, and it has been rising for 14 weeks. Nobody can reliably say which way a price will move, and this site does not try (as of 3 November 2026). ### Where is Clover Health Investments in its business cycle? Clover Health Investments, Corp.'s FY25 operating margin was −4.4%, against a 5-year range of −46.8% to −3.4%: the middle of its own range, neither a peak nor a low. The latest quarter was 3.8%. Comparing margins with a company's own long history is a good way to see where it is in its cycle (as of 3 November 2026). ### What could break the Clover Health Investments story? Biggest thing to watch: the price has already been rising for 14 weeks, so timing is the risk more than the business. On price, this page treats a rise as over when the share price closes below its 200-day average on two Fridays in a row (as of 3 November 2026). ### Is Clover Health Investments a stock worth studying right now? What the numbers show: Clover Health Investments, Corp.'s share price, valuation and earnings point in different directions. The next one or two quarters should make it clearer. The main open question: the next one or two quarters of results. Every number on this page is worked out by code from the published figures, with no forecasts and no price opinions (as of 3 November 2026). This is research, not advice. We’re not SEBI-registered.